1)Mangili G, Sigismondi C, Gadducci A, Cormio G, Scollo P, Tateo S, et al.Outcome and risk factors for recurrence in malignant ovarian germ cell tumors: a MITO-9 retrospective study.Int J Gynecol Cancer.2011; 21:1414-21.
2)Pectasides D, Pectasides E, Kassanos D.Germ cell tumors of the ovary. Cancer Treat Rev. 2008;34:427–41.
3)Goyal LD, Kaur B, Badyal RK. Malignant Mixed Germ Cell Tumors of the Ovary: A Series of Rare Cases.J Reprod Infertil. 2019;20:231-236.
4)Mangili G, Sigismondi C, Lorusso D, Cormio G, Candiani M, Scarfone G et al .The role of staging and adjuvant chemotherapy in stage I malignant ovarian germ cell tumors (MOGTs): the MITO-9 study.Annals of Oncology. 2017; 28: 333–338.
5)Anita AN, Rushdan MN .Reproductive function after treatment of ovarian germ cell malignancy. Med J Malaysia. 2012;67:71-6.
6)Low JJH, Ilancheran A, Ng JS .Malignant ovarian germ-cell tumours. Best Pract Res Clin Obstet Gynaecol. 2012; 26:347–55.
7)Park JY, Kim DY, Suh DS, Kim JH, Kim YM, Kim YT,et al.Analysis of outcomes and prognostic factors after fertility-sparing surgery in malignant ovarian germ cell tumors. Gynecol Oncol.2017;145:513–8.
8) Lambertini M, Dellepiane C, Viglietti G, Del Mastro L.Pharmacotherapy to protect ovarian function and fertility during cancer treatment. Expert Opin Pharmacother.2017;18(8):739-742.
9)Ray-Coquard I, Morice P, Lorusso D, Prat J, Oaknin A, Pautier P, Colombo N; ESMO Guidelines Committee.Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol.2018;29 .doi: 10.1093/annonc/mdy001.
10) Brown J, Friedlander M, Backes FJ, Harter P, O'Connor DM, de la Motte Rouge T,et al.Gynecologic Cancer Intergroup (GCIG) consensus review for ovarian germ cell tumors.Int J Gynecol Cancer.2014;48-54
11) Kang H, Kim TJ, Kim WY, Choi CH, Lee JW, Kim BG, Bae DS. Outcome and reproductive function after cumulative high-dose combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for patients with ovarian endodermal sinus tumor. Gynecol Oncol.2008;111:106-10.
12) Smith HO, Berwick M, Verschraegen CF, Wiggins C, Lansing L, Muller CY ,et al. Incidence and survival rates for female malignant germ cell tumors. Obstet Gynecol.2006;107:1075-85.
13) Turkmen O, Karalok A, Basaran D, Kimyon GC, Tasci T, Ureyen I ,et al. Fertility-Sparing Surgery Should Be the Standard Treatment in Patients with Malignant Ovarian Germ Cell Tumors. J Adolesc Young Adult Oncol.2017;6:270-276.
14) Hohmann C, Borgmann-Staudt A, Rendtorff R, Reinmuth S, Holzhausen S, Willich SN, et al. Patient counselling on the risk of infertility and its impact on childhood cancer survivors: results from a national survey. J Psychosoc Oncol.2011;29:274-85.
15) Prat J.FIGO Committee on Gynecologic Oncology. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet.2014;124:1-5.
16) Kaku T, Ogawa S, Kawano Y, Ohishi Y, Kobayashi H, Hirakawa T,et al. Histological classification of ovarian cancer. Med Electron Microsc.2003;36:9-17.
17) Lo Presti A, Ruvolo G, Gancitano RA, Cittadini E. Ovarian function following radiation and chemotherapy for cancer. Eur J Obstet Gynecol Reprod Biol. 2004;1:33-40.
18) Smith HO, Berwick M, Verschraegen CF, Wiggins C, Lansing L, Muller CY,et al. Incidence and survival rates for female malignant germ cell tumors. Obstet Gynecol. 2006;107:1075-85.
19) Liu Q, Ding X, Yang J, Cao D, Shen K, Lang J,et al. The significance of comprehensive staging surgery in malignant ovarian germ cell tumors. Gynecol Oncol. 2013;131:551-4.
20) Palenzuela G, Martin E, Meunier A, Beuzeboc P, Laurence V, Orbach D, et al. Comprehensive staging allows for excellent outcome in patients with localized malignant germ cell tumor of the ovary. Ann Surg.2008;248:836-41.
21) Nasioudis D, Frey MK, Chapman-Davis E, Caputo TA, Holcomb K. Fertility-preserving surgery for advanced stage ovarian germ cell tumors. Gynecol Oncol.2017;147:493-496.
22) Oktay K, Harvey BE, Loren AW. Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update Summary. J Oncol Pract.2018;14(6):381-385.
23) Elbrashy AA, Kamal A, Fahim MI. Methods of Treatment and Outcome for Ovarian Germ Cell Tumors. Indian J Surg Oncol.2019;10:640-642.
24) Chan JK, Tewari KS, Waller S, Cheung MK, Shin JY, Osann K, et al. The influence of conservative surgical practices for malignant ovarian germ cell tumors. J Surg Oncol. 2008;98:111-6.
25) Cicin I, Eralp Y, Saip P, Ayan I, Kebudi R, Iyibozkurt C,et al.Malignant ovarian germ cell tumors: a single-institution experience. Am J Clin Oncol.2009 ;32:191-6. 26) Solheim O, Tropé CG, Rokkones E, Kærn J, Paulsen T, Salvesen HB, et al. Fertility and gonadal function after adjuvant therapy in women diagnosed with a malignant ovarian germ cell tumor (MOGCT) during the "cisplatin era". Gynecol Oncol. 2015;136(2):224-9.
27) Tomao F, Di Pinto A, Sassu CM, Bardhi E, Di Donato V, Muzii L, et al. Fertility preservation in ovarian tumours.Ecancermedicalscience. 2018;12:885.
28) Lee SJ, Schover LR, Partridge AH, Patrizio P, Wallace WH, Hagerty K,et al. American Society of Clinical Oncology. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol.2006;24(18):2917-31.
29) Del-Pozo-Lérida S, Salvador C, Martínez-Soler F, Tortosa A, Perucho M, Giménez-Bonafé P. Preservation of fertility in patients with cancer (Review). Oncol Rep. 2019;41(5):2607-2614.
30) Lo Presti A, Ruvolo G, Gancitano RA, Cittadini E. Ovarian function following radiation and chemotherapy for cancer. Eur J Obstet Gynecol Reprod Biol. 2004;113:33-40.
31) Chen Y, Luo Y, Han C, Tian W, Yang W, Wang Y, et al. Ovarian dysgerminoma in pregnancy: A case report and literature review. Cancer Biol Ther. 2018;19:649-658.
32) Zhang R, Sun YC, Zhang GY, Wu LY, Zuo J. Treatment of malignant ovarian germ cell tumors and preservation of fertility.Eur J Gynaecol Oncol.2012;33:489-92.
33) Zanetta G, Bonazzi C, Cantù M, Binidagger S, Locatelli A, Bratina G, et al.Survival and reproductive function after treatment of malignant germ cell ovarian tumors. J Clin Oncol.2001;19:1015-20.
34) Gershenson DM, Miller AM, Champion VL, Monahan PO, Zhao Q, Cella D,et al. Gynecologic Oncology Group. Reproductive and sexual function after platinum-based chemotherapy in long-term ovarian germ cell tumor survivors: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25:2792-7
35) Yang B, Yu Y, Chen J, Zhang Y, Yin Y, Yu N, et al. Possibility of women treated with fertility-sparing surgery for non-epithelial ovarian tumors to safely and successfully become pregnant-a Chinese retrospective cohort study among 148 cases. Front Med. 2018;12(5):509-517. 29218679.
36) Johansen G, Dahm-Kähler P, Staf C, Flöter Rådestad A, Rodriguez-Wallberg KA. Fertility-sparing surgery for treatment of non-epithelial ovarian cancer: Oncological and reproductive outcomes in a prospective nationwide population-based cohort study. Gynecol Oncol. 2019;155(2):287-293.
37) Ottolina J, Mangili G, Sigismondi C, Vanni VS, Viganò P, Candiani M. Reproductive function assessment after surgery plus chemotherapy for germ cell ovarian tumors (MOGCT): novel clues deriving from the field of fertility preservation.Gynecol Endocrinol.2014;30:778-80.
38)Levi Setti PE, Porcu E, Patrizio P, Vigiliano V, de Luca R, d'Aloja P, et al. Human oocyte cryopreservation with slow freezing versus vitrification. Results from the National Italian Registry data, 2007-2011.Fertil Steril. 2014;102:90-95.
39) Low JJ, Perrin LC, Crandon AJ, Hacker NF. Conservative surgery to preserve ovarian function in patients with malignant ovarian germ cell tumors. A review of74 cases. Cancer. 2000;89:391-8.
40) Boyle KE, Vlahos N, Jarow JP. Assisted reproductive technology in the new millennium: part II. Urology. 2004;63:217-24.
41) Ceppi L, Galli F, Lamanna M, Magni S, Dell'Orto F, Verri D, et al. Ovarian function, fertility, and menopause occurrence after fertility-sparing
surgery and chemotherapy for ovarian neoplasms. Gynecol Oncol.2019;152:346-352.
42) Ghaemmaghami F, Hasanzadeh M, Karimi Zarchi M, Fallahi A. Nondysgerminomatous ovarian tumors: clinical characteristics, treatment, and outcome. A case-controlled study. Int J Surg. 2008;6:382-6.
43) Ghalleb M, Bouzaiene H, Slim S, Hadiji A, Hechiche M, Ben Hassouna J,et al. Fertility-sparing surgery in advanced stage malignant ovarian germ cell tumor: a case report. J Med Case Rep. 2017;11:350.